Applying the concept of the cancer-immunity cycle in this study allowed us to reveal the potential mechanisms of non-responsiveness to ICI relying on low immunogenicity of tumors with altered ALK and EGFR. Most of them demonstrated ID or IE TME reflecting the inefficiency of primary tumor cell recognition. This evidence concerns the gene ALK and cancer.